Mepolizumab
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Mepolizumab: From Eosinophilic Pneumonia to Thrombocytopenia Due to Immune Destruction
One-Sentence Summary
Mepolizumab was originally used for eosinophil-driven lung conditions (eosinophilic pneumonia and pulmonary eosinophilia). The TxGNN model predicts it may be effective for thrombocytopenia due to immune destruction, but the supporting evidence is thin: 0 clinical trials and 1 publication (a single case report).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Eosinophilic pneumonia; pulmonary eosinophilia (from the knowledge graph; no approved-indication text in the Singapore licence records) |
| Predicted New Indication | Thrombocytopenia due to immune destruction |
| TxGNN Prediction Score | 99.66% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Mepolizumab is known to be an anti-IL-5 antibody that depletes eosinophils, which is why it fits eosinophil-driven diseases such as eosinophilic pneumonia and pulmonary eosinophilia.
The link to immune thrombocytopenia is indirect. A single case report describes a patient with a steroid-resistant hypereosinophilic immune disorder and a mixed thrombotic microangiopathy who improved on mepolizumab. The benefit is plausibly due to controlling eosinophil-driven immune dysregulation, not to a direct effect on platelet autoimmunity (anti-platelet autoantibodies and Fc-gamma receptor-mediated platelet clearance). The high TxGNN score is a computational prediction and does not replace clinical evidence.
Most other top-ranked predictions (inherited platelet disorders such as Glanzmann thrombasthenia and pseudo-von Willebrand disease) have no plausible IL-5-related mechanism and likely reflect proximity in the knowledge graph. Filariasis has a loose eosinophil link, but depleting eosinophils could impair parasite defence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28648630 | 2018 | Case report | Blood Cells, Molecules & Diseases | Steroid-resistant hypereosinophilic immune disorder resolved with mepolizumab, with improvement in a mixed thrombotic microangiopathy |
A review of hypereosinophilic syndrome management including mepolizumab (PMID 20565230, 2010) was linked to the second-ranked prediction (primary release disorder of platelets), but it does not address platelet disorders directly.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16811P | NUCALA Solution for Injection in Pre-filled Syringe 40mg/0.4mL | Injection, solution | Not stated in the compiled data |
| SIN16172P | NUCALA Solution for Injection in Pre-filled Pen 100mg/mL | Injection, solution | Not stated in the compiled data |
| SIN16171P | NUCALA Solution for Injection in Pre-filled Syringe 100mg/mL | Injection, solution | Not stated in the compiled data |
All three licences are valid single-ingredient products from Glaxo Operations UK Ltd.
Safety Considerations
Please refer to the package insert for safety information. No drug interactions were found in the data compiled for this report, and no knowledge-graph contraindications were recorded.
Specific concerns for the predicted uses:
- Filariasis: eosinophil depletion could impair host defence against parasites.
- Neonatal thrombocytopenia: no safety or pharmacokinetic data exist for mepolizumab in neonates.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction rests on a single case report in a different condition (hypereosinophilic syndrome with thrombotic microangiopathy), with no trials and no established mechanism for IL-5 blockade in immune platelet destruction. The model score alone is not enough to proceed.
To proceed, the following is needed:
- Mechanism of action data and a clearer mechanistic hypothesis, for example whether an eosinophilic or Th2-skewed ITP subset exists
- Package insert warnings and contraindications from the HSA, so safety screening can be done
- Controlled or at least larger observational data in immune thrombocytopenia
- Approved indication text for the Singapore licences, to confirm the original-indication link
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.